Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. OncoTherapy Science's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was -687.28%.
As of today (2026-07-19), OncoTherapy Science's WACC % is 4.02%. OncoTherapy Science's ROIC % is -600.79% (calculated using TTM income statement data).
OncoTherapy Science earns returns that do not match up to its cost of capital. It will destroy value as it grows.
OncoTherapy Science (FRA:30O) ROIC % Explanation
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROIC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, OncoTherapy Science's WACC % is 4.02%. OncoTherapy Science's ROIC % is -600.79% (calculated using TTM income statement data).
OncoTherapy Science earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
OncoTherapy Science ROIC % Related Terms
OncoTherapy Science ROIC % Historical Data
* Premium members only.
The historical data trend for OncoTherapy Science's ROIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, OncoTherapy Science's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoTherapy Science ROIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoTherapy Science's ROIC % distribution charts can be found below:
* The bar in red indicates where OncoTherapy Science's ROIC % falls into.
Note:
The Operating Income data used here is two times the semi-annual (Mar. 2026) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoTherapy Science (FRA:30O) has a ROIC % of -687.28% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on OncoTherapy Science and its competitors.
Is OncoTherapy Science's ROIC % too high?
OncoTherapy Science's current ROIC % is -687.28%. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's ROIC % compare to VRTX and REGN?
OncoTherapy Science's ROIC % of -687.28% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current ROIC % is -687.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (FRA:30O) is currently considered Fairly Valued. The stock's GF Value™ is €0.08, compared to a current price of €0.08 — trading 3.1% above its estimated fair value. The current ROIC % is -687.28%. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For OncoTherapy Science (FRA:30O), the current ROIC % is -687.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoTherapy Science (FRA:30O) Overvalued in 2026?
Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued.
The current stock price of €0.08 is trading 3.1% above its estimated GF Value™ of €0.08.
GuruFocus considers OncoTherapy Science to be Fairly Valued.
Key valuation signals for FRA:30O:
ROIC %: -687.28%
GF Value™: €0.08 vs. price of €0.08 (3.1% above fair value)
No single metric tells the full story. See the FRA:30O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score
Get the complete analysis for FRA:30O
ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:30O has been successfully added to your 
